Werner Hilgers

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Mieke Schutte, Ralph H. Hruban, Joseph Geradts et al. · PubMed · 1997 · 665 citations

Tumor Biology, Pancreatic Cancer, Medicine +13

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+.

Michael Goggins, G. J. A. Offerhaus, Werner Hilgers et al. · PubMed · 1998 · 271 citations

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer

Eric S. Calhoun, Jessa Jones, Raheela Ashfaq et al. · American Journal Of Pathology · 2003 · 228 citations · Full text

Tumor Biology, Pancreatic Cancer, Somatic Variant +8